Northwest Biotherapeutics, Inc. (NWBO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.53-0.02 (-3.55%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.55
Bid0.53 x 1000
Ask0.56 x 3800
Day's Range0.52 - 0.57
52wk Range0.32 - 6.90
1y Target EstN/A
Market Cap60.57M
P/E Ratio (ttm)-2.00
Avg Vol (3m)2,082,603
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com7 hours ago

    Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

    Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.

  • PR Newswire3 days ago

    NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London

    BETHESDA, Md., Sept. 21, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer, today presented an updated and more detailed analysis of the Phase I DCVax®-Direct Trial data at the 5th Annual SMi Cancer Vaccines Conference in London, England. DC Vax-Direct is designed to treat inoperable solid tumors.  The Phase I Trial treated patients with multiple inoperable metastatic tumors who had failed existing treatment regimens.  These patients had failed as many as five or six different prior types of treatments, and had generally quite poor life expectancies when they entered the DCVax-Direct Trial.  DCVax-Direct was directly injected, with image guidance, into just one of the patients' tumors and most patients received just three treatments.  The Trial included 40 patients, with 39 evaluable, and covered more than a dozen diverse types of solid tumor cancers.

  • Capital Cube11 days ago

    ETF’s with exposure to Northwest Biotherapeutics, Inc. : September 13, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETF’s with the largest exposure to NWBO-US. Comparing the performance and risk of Northwest Biotherapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)